Skip to main content

Main menu

  • Pipeline
    • Clinical
    • Discovery
    • Compounds
    • Regimens
    • Drug Targets
    • Developers
    • Trial Sites
    • Trials
  • News
  • Meetings
  • Members
    • Our Members
    • Core Group
  • About
  • Join Us
Regimen

Delamanid with OBR

Compounds in Regimen
Delamanid
Optimized Background Regimen (OBR)
Description
Trial Associations
Delamanid with OBR for MDR TB
Developer Associations
Otsuka Pharmaceutical Development & Commercialization, Inc.
Downloads
Six-Month Response to Delamanid Treatment in MDR TB Patients
Early Outcomes of MDR-XDR TB Compassionate Use
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug Resistant Tuberculosis
  Would you like to receive updates from the WGND? Join our mailing list:
Interests

About Us

Part of Stop TB Partnership, we are a network of committed individuals devoted to accelerating the development of effective, affordable new therapies for TB.

Visit the Stop TB Partnership
Read about The Global Plan to End TB

Navigate

  • Clinical Pipeline
  • Discovery
  • Developers
  • Trials
  • Trial Sites
  • News
  • Meetings
  • Core Group
  • Members
  • About

Contact

The Working Group for New TB Drugs

80 Pine Street, Fl 20th
New York, NY

Contact Us

Follow Us

©2016 Working Group on New TB Drugs. All Rights Reserved. Terms of Reference Site by Darby Communications